SEC Form 4 · accession 0001209191-18-061334
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carole Ho
Officer — Chief Medical Officer
Period of report
Dec 3, 2018
Accepted (ET)
Dec 6, 2018 · 5:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF4,F5 | Dec 3, 2018 | S | 17,100 | $18.431 | D | 148,790 | I | See footnote |
| Common StockF6,F5 | Dec 3, 2018 | S | 400 | $19.16 | D | 148,390 | I | See footnote |
| Common StockF1 | holding | — | — | — | 46,875 | D | ||
| Common StockF2 | holding | — | — | — | 25,000 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares are held of record by Carole Ho and Rajat Rohatgi.
- F2The shares are held of record by the Rohatgi-Ho Irrevocable GST Trust, for which Reporting Person serves as trustee.
- F3The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- F4The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.07 to $18.87 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F5The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
- F6The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.15 to $19.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.